JP Morgan Chase
GLUE icon

JP Morgan Chase’s Monte Rosa Therapeutics GLUE Stock Holding History

JP Morgan Chase’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Buy
76,820
+9,284
+14% +$175K ﹤0.01% 4248
2026
Q1 		$1.05M Buy
67,536
+43,416
+180% +$830K ﹤0.01% 4581
2025
Q4 		$378K Buy
24,120
+1,181
+5% +$15.9K ﹤0.01% 5201
2025
Q3 		$170K Sell
22,939
-1,941
-8% -$10.3K ﹤0.01% 5604
2025
Q2 		$112K Buy
24,880
+921
+4% +$4.11K ﹤0.01% 5553
2025
Q1 		$111K Sell
23,959
-135
-0.6% -$828 ﹤0.01% 5519
2024
Q4 		$167K Buy
24,094
+5,551
+30% +$41.7K ﹤0.01% 5557
2024
Q3 		$98.3K Buy
18,543
+5,125
+38% +$25.9K ﹤0.01% 5707
2024
Q2 		$50.2K Buy
13,418
+597
+5% +$3.04K ﹤0.01% 5861
2024
Q1 		$90.4K Sell
12,821
-9,215
-42% -$54.7K ﹤0.01% 5712
2023
Q4 		$125K Sell
22,036
-7,418
-25% -$29.1K ﹤0.01% 5633
2023
Q3 		$141K Buy
29,454
+4,026
+16% +$25.9K ﹤0.01% 5279
2023
Q2 		$174K Buy
25,428
+1,028
+4% +$6.65K ﹤0.01% 5157
2023
Q1 		$190K Buy
24,400
+6,064
+33% +$42.2K ﹤0.01% 5093
2022
Q4 		$140K Sell
18,336
-707
-4% -$5.89K ﹤0.01% 5205
2022
Q3 		$156K Buy
19,043
+1,335
+8% +$12.3K ﹤0.01% 5060
2022
Q2 		$171K Sell
17,708
-4,804
-21% -$48.3K ﹤0.01% 5153
2022
Q1 		$316K Buy
22,512
+10,838
+93% +$150K ﹤0.01% 4953
2021
Q4 		$239K Buy
11,674
+7,242
+163% +$152K ﹤0.01% 5250
2021
Q3 		$99K Buy
+4,432
New +$127K ﹤0.01% 5575

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's GLUE Position: Q2 2026 in Review

JP Morgan Chase increased its Monte Rosa Therapeutics (GLUE) stake by 14% in Q2 2026, buying an estimated $175K and bringing the position to 76,820 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4248.

JP Morgan Chase first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • JP Morgan Chase held 76,820 shares of Monte Rosa Therapeutics worth $1.84M as of Q2 2026.
  • JP Morgan Chase bought 9,284 Monte Rosa Therapeutics shares in Q2 2026, an estimated $175K.
  • Monte Rosa Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4248 holding.
  • JP Morgan Chase first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.